Morris, Patrick J.

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,609

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 1,260

Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability

Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 271

Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer

Sayin, V. I., LeBoeuf, S. E., Singh, S. X., Davidson, S. M., Biancur, D., Guzelhan, B. S., Alvarez, S. W., Wu, W. L., Karakousi, T. R., Zavitsanou, A. M., et al. (2017) · eLife

Genomics, phytochemicals, and oxidative stressCancer, Hypoxia, and Metabolism

Cited by 231

Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function

Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 158

( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions

Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 152

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications

Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 92

Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites

Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 83

(R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses

Zanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 82

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R )-hydroxynorketamine

Highland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology

Treatment of Major DepressionPharmacogenetics and Drug Metabolism

Cited by 62